These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29860261)

  • 1. Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.
    Takaki H; Ichimiya S; Matsumoto M; Seya T
    J Innate Immun; 2018; 10(5-6):515-521. PubMed ID: 29860261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
    Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
    Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells.
    Pizzolla A; Wang Z; Groom JR; Kedzierska K; Brooks AG; Reading PC; Wakim LM
    Proc Natl Acad Sci U S A; 2017 May; 114(20):5225-5230. PubMed ID: 28461487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
    Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
    J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
    Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
    Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
    Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
    PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nasal vaccines].
    Kido H; Mizuno D; Takei T
    Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity.
    Sanchez-Guzman D; Le Guen P; Villeret B; Sola N; Le Borgne R; Guyard A; Kemmel A; Crestani B; Sallenave JM; Garcia-Verdugo I
    Biomaterials; 2019 Oct; 217():119308. PubMed ID: 31279103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.